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Qualitative analysis of clinicians’
perspectives on the use of a computerized
decision aid in the treatment of psychotic
disorders
Lukas O. Roebroek1,2,3* , Jojanneke Bruins1,2, Philippe Delespaul4,5, Albert Boonstra6 and Stynke Castelein1,2,3
Abstract
Background: Clinical decision aids are used in various medical fields to support patients and clinicians when
making healthcare decisions. Few attempts have been made to implement such tools in psychiatry. We developed
Treatment E-Assist (TREAT); a routine outcome monitoring based computerized clinical decision aid, which
generates personalized treatment recommendations in the care of people with psychotic disorders. The aim of this
study is to investigate how TREAT is used and evaluated by clinicians and how this tool can be improved.
Methods: Clinicians working with TREAT during a clinical trial were asked to participate in semi-structured interviews. The
Unified Theory of Acceptance and Use of Technology (UTAUT) was used as a sensitizing theory to structure a part of the
interview questions. The transcripts were analyzed using inductive thematic analysis to uncover the main themes.
Results: Thirteen clinicians (mean age: 49) of which eight psychiatrists and five nurse practitioners, participated in this
study. Eight clinicians experienced TREAT as beneficial, whereas five experienced no additional benefits. Thematic analysis
revealed five themes surrounding usage and evaluation of TREAT, views on TREAT’s graphic representation of routine
outcome monitoring results, guideline based treatment recommendations, contextual factors, effects on patients and
effects on shared decision-making. Performance and effort expectancy were perceived as high by clinicians. The
facilitating conditions were optimal and perceived social influence was low.
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Conclusion: This article presents a qualitative evaluation by clinicians of a computerized clinical decision aid in psychosis
care. TREAT was viewed by most clinicians as beneficial during their consultations. The graphic representation of routine
outcome monitoring results was well-appreciated and provided input to discuss treatment planning with patients. The
treatment recommendations did not change most treatment decisions but supported clinical reasoning. However, some
clinicians were unconvinced about TREAT’s benefits. The delivery, applicability and the availability of resources require
improvement to increase TREAT’s efficacy. Not all patients responded well to TREAT but the observed facilitation of
shared decision-making is promising. All four predictors of the Unified Theory of Acceptance and Use of Technology were
positively evaluated by the majority of clinicians.




When patients and clinicians draft treatment plans, there
are many things to consider. There may be multiple options
with no clear, best choice. Clinical decision aids (CDAs)
aim to facilitate and improve therapeutic decision-making.
They help professionals and patients agree on important
treatment options [1]. CDAs do so by assessing needs and
providing evidence-based information about treatment op-
tions including risks and benefits [1]. Despite the effective-
ness of these tools [2], their integration in daily clinical
practice remains limited [3, 4]. Less than half of all CDAs
are still used after the experimental evaluation period [4].
This is due to a lack of funding or endorsement by organi-
zations, because the tools are out of date or do not fit the
existing care processes [4]. Aligning CDAs with guidelines,
care standards, clinical policies, existing infrastructure and
workflows can augment their uptake within organizations
[5]. Often, clinicians remain unconvinced of the benefits of
CDAs [6], arguing that they do not agree with their content
and use or simply lack time to implement them in their
daily clinical practice [4]. Therefore, it is important to in-
volve clinicians in different stages of development of new
CDAs and critically evaluate their functionality.
TREAT
CDAs could benefit psychiatric care, as patients gener-
ally have multiple complex care needs, while clinicians
often make treatment decisions based on personal pref-
erences [7]. CDAs can reduce the knowledge-gap be-
tween available treatments and potential outcomes. They
can improve reflection about personal preferences by
providing feedback on risk and benefits of specific inter-
ventions, for example when deciding on psychiatric
medication [2]. Unfortunately, CDAs are poorly imple-
mented and rarely used in psychiatric care. A systematic
review of 105 clinical trials of CDAs only included three
studies in mental health [2]. These tools reduced deci-
sional conflict and increased knowledge about treatment
options for patients with depressive [8] and post-
traumatic stress disorders [9]. One CDA facilitated
shared decision-making (SDM) for patients with psych-
otic disorders [10]. To improve adoptation of CDAs in
psychosis care, Lentis Psychiatric Institute developed a
computerized CDA: Treatment E-Assist (TREAT) [11].
TREAT is the first CDA in psychosis care that combines
routine outcome monitoring (ROM) data with current treat-
ment guidelines and care standards to provide clinicians and
patients with personalized evidence-based treatment recom-
mendations. Care providers in the Northern-Netherlands
use an extensive ROM-screening in psychosis care called the
Pharmacotherapy Monitoring and Outcome Survey (ROM-
PHAMOUS) [12]. Routine outcome data are ideally used to
draft treatment plans during annual consultations. There is
no formal procedure for integrating these data into daily
clinical practice. As such the way information from ROM-
PHAMOUS is directly used to guide treatment varies
between institutions, teams and clinicians. Although ROM-
PHAMOUS is effective in identifying care needs, these needs
are not always met with appropriate care [13, 14]. TREAT
was designed to bridge the gap between ROM-data and
treatment choice by offering customized treatment recom-
mendations to discuss during the annual treatment plan
evaluations. TREAT is evaluated on its clinical effectiveness
in improving care in a multicenter study.
Research aim
The focus of this study is on the usage and evaluation of
TREAT by clinicians. Three aims were formulated: 1) assess
how clinicians use TREAT during consultations, 2) gain
greater understanding in user acceptance by investigating
how clinicians evaluated TREAT, and finally 3) collect infor-
mation on how to improve the application for future use.
Method
Study setting and participants
During the trial, clinicians were asked to use TREAT,
each with four different patients, during their annual
treatment plan evaluations. In total, 33 clinicians en-
rolled in the trial of which 27 actually worked with the
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TREAT application. In-depth interviews were conducted
with those clinicians who used TREAT with at least
three different patients. In total, 13 clinicians who met
this criterion were approached and agreed to participate.
They worked in 11 different flexible assertive community
treatment (FACT) teams of four mental healthcare
institutions.
Study design
A descriptive qualitative design was used to gain insights
into the experiences and attitudes of clinicians who
worked with TREAT. The Unified Theory of Acceptance
and Use of Technology (UTAUT, Fig. 1) [15] was used
as a sensitizing theory to structure our semi-structured
interview guide, as shown in additional file 1. This model
is a reference to explore an individual’s intention to
adopt a technological innovation in an organizational
setting. In the UTAUT model performance expectancy,
effort expectancy, social influence and facilitating condi-
tions predict usage behavior [15]. These predictive fac-
tors are moderated by gender, age, experience
(occupation and years working in psychosis care) and
voluntariness of use [15]. Additional questions struc-
tured in accordance with our research aim were added
to the interview guide (see additional file 1) such as “In
what way did you use TREAT?” or “What was the effect
of TREAT on your clinical encounters?”
Data collection
All data was collected between July and September of
2019. Clinicians were invited through telephone calls to
participate in this study and interviews were planned
with those who were willing to participate. All interviews
took place in the office of clinicians. The assessment
started with a brief introduction to explain the goals of
the interview and to sign the informed consent. Subse-
quently, the semi-structured interview was conducted by
the first author (LR) based on the interview guideline.
All questions were open and the researcher asked in-
depth questions to further elucidate unclear or ambigu-
ous information. The interviews lasted between 15 and
45min. All interviews were digitally recorded and tran-
scribed verbatim. Our goal was to identify as many rele-
vant themes as possible. No new information or themes
emerged after 13 interviews after which data saturation
was assumed and data collection was stopped [16].
Data analysis
We analyzed the data using an inductive thematic analysis
approach [17]. With the use of the qualitative data analysis
software of ATLAS Ti version 8.4, every transcript was
coded line-by-line by the first author to identify patterns
and gaps in the data. Two hundred seventy-three codes
were identified. Using an inductive approach, the research
team identified themes from the codes [18]. Finally, the re-
search team discussed the themes on relevance until con-
sensus was reached.
Results
We interviewed 13 professionals: eight psychiatrists and
five nurse practitioners. The average participant age was
49, seven were female and their average experience with
working in psychosis care was 17 years (Table 1). Eight
clinicians experienced the application as overall benefit-
ing their clinical encounters, whereas five experienced
no or even a negative impact on their daily clinical
Fig. 1 Unified theory of acceptance and use of technology
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practice. The research group identified five recurrent
themes in the interviews: 1) graphic representation, 2)
guideline based treatment recommendations, 3) contextual
factors, 4) effects on patients and 5) effects on shared
decision-making. These themes were appraised differently
by the respondents and provided new insights into the way
TREAT was used during consultations and contained feed-
back that can be used to improve TREAT for future use.
Theme 1: Views on TREAT’s graphic representation
Before the introduction of TREAT, ROM results were
summarized in a letter to the clinicians and the general
practitioner (i.e. ‘ROM-letter’). It contains a written descrip-
tion of the ROM results. The TREAT application presents
ROM results graphically and structures it in three areas
(symptoms, physical health and psychosocial wellbeing, Fig.
2). This representation was frequently discussed. The ma-
jority of the respondents indicated that, compared to the
ROM-letter, TREAT reports were an improvement. Data is
better structured and more appealing. The graphs made it
easier to identify and interpret issues and the visualization
improved the discussion with patients. One clinician noted:
“It’s a really good instrument to interpret the ROM-
results and to take action if needed. It makes things
a lot easier. With the ROM-letter, “you had to figure
out what should be discussed with the patient, and
which matters were less important. With TREAT it’s
much more obvious, so yeah, it’s much easier.” [C1]
Another clinician emphasized the visualization of out-
liers in the results:
“TREAT is very user-friendly and the graphs also
make it very visual. People were able to really see
the outliers in their results, which gives me the op-
portunity to specifically discuss them. It gives people
guidance and support during the consult.” [C8]
However, some clinicians indicated that TREAT added
little value to their already structured routine:
“Let me start by saying that our ROM-letter, which
we have been using for years, has a clear overview of
all ROM results. Therefore, I am already used to
evaluate these results systematically with my pa-
tients. With TREAT this remains the same albeit in
a different visual representation with graphs and
treatment recommendations.” [C12]
While some clinicians felt TREAT complicated their
routine:
“I always used the ROM-letter myself to check for
any particularities, somehow there always seemed to
be less than with TREAT. Now the focus is on many
more areas, so you almost need to prepare ahead of
time.” [C5]
Overall, the representation of the ROM-results was well-
appreciated by most clinicians and seen as an improve-
ment compared to the previous ROM-letter. Graphic
representation of the ROM-results made pressing issues
in treatment more visible and therefore easier to discuss.
Based on the UTAUT model, TREAT’s graphic repre-
sentation positively affected the predictive factors of ef-
fort and performance expectancy.
Theme 2: Views on TREAT’s treatment recommendations
TREAT offers several treatment recommendations
(Fig. 3) for clinicians to consider with their patients.
Some clinicians found these recommendations helpful:
“That’s what I like about TREAT; you are not forced
to follow for example a recommendation to start an
anti-depressant in case of persistent negative symp-
toms. You just discuss it, like is this something you
would prefer or not. Maybe you both decide to try
something else. Either way the recommendation is
still valid, it’s just not mandatory.” [C6]
However, others found the recommendations bother-
some or felt pressured:
“I mean, I know it’s not mandatory to follow the rec-
ommendations, but it still feels that way. Sometimes,
you’re just happy that somebody is using the medica-
tion you prescribe at all, and then you get the recom-
mendation to switch the medication. TREAT seems
Table 1 Clinician demographics
Clinician Occupation Age range Years in psychosis care
1 Psychiatrist 61–65 23
2 Psychiatrist 41–45 3
3 Nurse practitioner 41–45 21
4 Psychiatrist 66–70 33
5 Psychiatrist 41–45 11
6 Nurse practitioner 41–45 20
7 Psychiatrist 56–60 23
8 Psychiatrist 36–40 5
9 Nurse practitioner 36–40 20
10 Psychiatrist 51–55 19
11 Nurse practitioner 61–65 15
12 Psychiatrist 41–45 15
13 Nurse practitioner 46–50 12
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to always tell you that it’s not good enough. It’s never
good enough.” [C13]
Even though the tone of the treatment recommenda-
tions was experienced in different ways, all clinicians
agreed that the actual content of the recommendations
was sound. However, opinions on the applicability varied.
Several clinicians experienced the suggestions as generic
and comprehensive, sometimes even too comprehensive.
Not all recommendations were suited for the clinical com-
plexity of the patient, or had already been tried before:
“The treatment recommendations are sound but you
always need to tailor them to a specific patient or
circumstance and see if they still apply.... It’s difficult
because sometimes certain recommendations from
guidelines have already been tried or are not applic-
able anymore.” [C2]
Although several clinicians raised the issue of utility,
most of them had checked the utility and relevancy of
the recommendations for each individual patient and
found ways to incorporate them into their consultations.
The recommendations were used to evaluate previous
steps and to discuss and decide on current treatment
plans, as this respondent explained:
“TREAT is helpful in aligning treatment with the
evidence-based recommendations. It can be used to
start a conversation about treatment options and
help explain why alternative treatment options
might be more preferable.” [C11]
Other clinicians used the recommendations to discuss
possible future steps in the treatment process:
“TREAT also provides information about possible
future steps in treatment such as for example
electroconvulsive therapy. If recommendations are
presented on a screen it feels more natural to address
it as an option. You can inform patients of different
options in case the current treatment doesn’t work.”
[C8]
However, some clinicians did not see the recommenda-
tions as beneficial. They argued that they were well
Fig. 2 Example of the graphic data representation
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aware of the content of existing guidelines and therefore
did not need an overview of the different guideline-
recommended treatment options, as this respondent
stated:
“TREAT was not beneficial in reminding me of new
things we could try for a specific problem. It’s not
really a lack of knowledge I experience when drafting
a treatment plan or when starting a new treatment.”
[C12]
Some respondents even experienced the recommenda-
tions as irritating:
“I feel guidelines are necessary as a foundation but
we can also assume they are well-known. To build a
system just to beat people over the head with guide-
lines defeats its purpose. It irritates.” [C10]
Overall, opinions on the recommendations varied. Some
respondents actively used the recommendations during
their consultations while others felt no need for guide-
line implementation. Multiple suggestions were made to
shorten the text and to make recommendations more
personalized. It is important to look for ways to improve
these recommendations, as a perceived lack of utility
could potentially prevent clinicians from working with
TREAT after this clinical trial.
Theme 3: Views on TREAT’s contextual factors
All clinicians agreed that TREAT was properly imbed-
ded into the existing technical infrastructure of the elec-
tronic patient record. Therefore, the facilitating factor
referred by the UTAUT model was perceived as optimal
and enhanced TREAT’s use. Clinicians who experienced
TREAT as benefiting their practice found it easier to in-
corporate the application into their routines. Teams that
used a strict screening routine, organized processing of
the screening data and structured scheduling of treat-
ment plan evaluations, were most successful at imple-
menting TREAT. Some teams used the opportunity of
the TREAT study to improve their screening process
and feedback procedure, as this clinician highlighted:
“We chose to participate in the TREAT study and to
make TREAT the driving force behind our evalua-
tions and yearly screenings.” [C9]
Getting used to a tool such as TREAT, even if ultimately
intended as a time-saver, takes time [15]. Most teams in-
dicated, however, that they simply did not have that
time, as they were understaffed. Some clinicians
Fig. 3 Example of treatment recommendations
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indicated that the TREAT application made their con-
sultations more time efficient. However, the majority ex-
perienced either no difference or reported increased
consultation times. Most clinicians had to become famil-
iar with TREAT and find ways to use it effectively dur-
ing consultations:
“You really need to work with it [TREAT] a few
times because you can get questions for which you
were not prepared or reminded of things you might
have missed.” [C7]
Apart from novelty, TREAT also increased consultations
times by bringing up a larger array of topics for
discussion:
“I think my consultations became longer, because I
noticed some time shortage. Therefore, you probably
take or just need some more time to discuss all the
results. It depends of course, on what ends up in
TREAT. If someone has few problems you are
quicker to discuss everything.” [C12]
This is in part because the ROM-PHAMOUS screening is
extensive and patients often experience issues in multiple
areas. Furthermore, an incomplete screening was men-
tioned several times as a limiting factor. Clinicians some-
times chose not to use TREAT during a consultation
because questionnaires were missing. In addition, more
than half of the clinicians indicated that some of the rec-
ommended interventions were not part of the available
treatment resources within their team. In some teams,
nearly all of the recommended interventions were unavail-
able. Psychomotor therapy (PMT) was mentioned most
frequently as a missing resource, followed by cognitive be-
havioral therapy (CBT), eye movement desensitization
and reprocessing (EMDR) and individual placement and
support (IPS). Clinicians generally ignored unavailable rec-
ommendations during consultations, thereby potentially
decreasing TREAT’s efficacy. In some cases, TREAT moti-
vated clinicians to recruit professionals for missing re-
sources elsewhere in their organization:
“I really feel a lot of the added value lies in the fact
that we are used to recommending treatments we
have available. TREAT reminds you of treatments
you do not have available directly, so you can try
and find those treatments elsewhere within the
organization.” [C8]
Compared to most CDAs in fields such as oncology, car-
diology or orthopedics [2], psychiatry differs from set-
tings in which CDAs have found mass adoption because
care for patients in FACT teams is mostly integrated in
long lasting recovery based processes [19]. Treatment de-
cisions fit in an approach in which timing of interventions
is important. Interventions should be available at various
times throughout the treatment process. Moreover, psych-
otic illness is periodic and the decision-making process
should match this process-based variability. It was men-
tioned several times that it is not always straightforward
to turn treatment recommendations into behavioral
changes for this patient group:
“Most people have been in care for a long time and
suffer from several disabilities. Sometimes you are
able to initiate something new by putting in a lot of
effort, but sometimes it just does not work because
some patients have been doing things in a certain
way for so long it’s difficult to motivate them to try
things in a new way.” [C7]
On the other hand, some clinicians actually used TREA
T as a driving force to try new steps in treatment with-
out postponing them:
“I think it [TREAT] helps clinicians to stay closer to
and be more professional in chronic treatment while
remaining evidence-based without postponing the
next step in treatments.” [C8]
To summarize, structured and complete ROM screenings
facilitate the use of TREAT. Consultations need to be
strictly planned after screenings and might take more
time. Missing treatment resources within teams can lower
the efficacy of TREAT and hamper its implementation.
Theme 4: Views on TREAT’s effects on patients
The effects of TREAT on individual patients were a re-
curring theme. The extent to which patients were en-
gaged in the use of TREAT varied. In most cases,
patients and clinicians sat together in front of a com-
puter screen to review the TREAT report. However,
some clinicians preferred to use the printed version.
Overall respondents noticed that sharing information
with TREAT did not work equally well for all patients.
Some had cognitive problems and were easily over-
whelmed by the complexity of the data presented in the
application:
“I noticed that if patients are not able to process a
lot of information at the same time or if they are
very much stuck in their own line of thinking, TREA
T’s systemic approach doesn’t really work that well.”
[C2]
Most clinicians indicated that they did not notice signifi-
cant changes in the therapeutic relation with their
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patients when using TREAT. However, some clinicians
did:
“We think that the traditional treatment relation-
ship between patient and clinician is fundamentally
changing, it is becoming more horizontal, not in
every aspect but in many. That is where it is sup-
posed to go. I really think TREAT can facilitate this
because it increases commitment and a feeling of
ownership.” [C4]
Another clinician noticed a greater sense of ownership
for patients while using TREAT:
“It really has to do with ownership of the data. If I
have a ROM-letter with a lot of text, it feels like I
own the data. With TREAT there is a subtle nuance
in how it feels, like you give the patient more owner-
ship and make them the owner of the data.” [C2]
Most clinicians viewed TREAT as an effective tool to en-
gage in conversation with patients about specific areas of
interest or suggested treatment recommendations:
“You can show your patients the different treatment op-
tions during the consultation and explain the risks and
benefits. I see it as a useful tool to engage in a conversa-
tion about the available treatment options.” [C3]
It was often mentioned that TREAT prevents you from
missing certain issues during consultations. This opens
up the opportunity to discuss these issues with patients,
as this respondent revealed:
“Of course, that’s the beauty of this system. TREAT
suggests things that you otherwise might have forgot-
ten or wouldn’t have thought of. Sometimes it can be
used to engage in conversation. For instance saying
something like: “According to the guidelines, you
would have to start with an antidepressant. What
do you think? Oh, you don’t want another pill?
Okay.” [C6]
Several clinicians indicated that it became easier to dis-
cuss intimate topics because they were explicitly stated
in TREAT. One respondent pointed out sexuality as an
example:
“For example sexuality. That is not something you
would immediately discuss, I mean you should of
course, so that is my fault, but with TREAT, it is ex-
plicitly stated. Also intimacy. It therefore brings itself
up, which makes you talk about it. So that’s an im-
provement.” [C4]
Some clinicians expressed concerns that TREAT fo-
cusses more on problems instead of strengths. Highlight-
ing the positive trends and aspects of treatment was
mentioned several times as a potential improvement.
Most clinicians have a recovery-oriented view on patient
care, which sometimes contradicted the alarming nature
of TREAT as this respondent explained:
“Our intention in our patient contact is to try to focus
on recovery and strengths. However, TREAT draws the
attention mostly to the negative points.” [C13]
In a few cases, patients experienced TREAT as confron-
tational and it even scared some:
“Sometimes I would notice a negative atmosphere,
caused by the results and how they are displayed. That’s
because it mostly highlights problems which pop up in
red graphs. That scared some patients.” [C12]
In sum, some clinicians noticed some patients did not
respond well to TREAT because it confused or scared
them. However, clinicians were able to use TREAT ef-
fectively during consultations with most of their patients.
Important and sensitive issues became apparent and
were therefore less likely to be forgotten which strength-
ened clinicians’ performance expectancy as referred to in
the UTAUT model.
Theme 5: Views on TREAT’s effects on shared decision-
making
A majority of clinicians indicated that TREAT supported
their clinical reasoning. It did not change the outcome
of most treatment decisions, but improved the way these
decisions were made. Even though clinicians held differ-
ent opinions regarding the benefits of TREAT, nearly all
of them agreed that it contributes to shared decision-
making (SDM):
“It [TREAT] did have a positive influence on shared
decision-making. You have multiple options to
choose from. That was most obvious with things like
negative symptoms. You can tell someone music
therapy or cognitive behavioral therapy is available,
but scrolling through these options together makes it
easier for patients to say: ‘that doesn’t suit me, but
this is something I’d like to try'.” [C8]
Another clinician provided a practical example of TREA
T contributing to SDM during a consultation:
“It [TREAT] improves your thinking. For example
with a patient suffering from depression and a guilt
delusion. For the delusion, it was recommended to
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start clozapine, but for the depression, the recom-
mendation was to start a lithium addition. You
explain and discuss these options. Eventually we
both agreed to start with the depression protocol,
before starting clozapine. We also agreed it was a
mood congruent delusion. TREAT really helps to
show things in this way.” [C11]
In conclusion, although respondents have different opin-
ions about the benefits and different aspects of TREAT,
they all agree that the application facilitates shared
decision-making. In total, five themes explain the use
and evaluation of TREAT by clinicians (Table 2). In
addition, all four predictors of the UTAUT model were
positively evaluated by the majority of the respondents.
Discussion
To the best of our knowledge, this is the first qualitative
study to examine the attitudes of clinicians working with
a CDA in psychosis care. Clinicians were the primary
focus of this study because they have to adopt TREAT
for successful implementation. Clinicians reported both
positive and negative experiences with the TREAT appli-
cation. Two groups emerged: those who experienced
TREAT as beneficial to their daily clinical practice and
those who did not. Psychiatrists were divided, while
nurse practitioners held the most positive attitudes.
Nurse practitioners were more willing to change their
normal consultation routines and use the guideline-
based treatment recommendations. Age and work ex-
perience in psychosis care, did not influence the use nor
evaluation of TREAT. Thematic analysis revealed five re-
current themes that provided insights into how TREAT
was used and perceived.
Many respondents mentioned time pressure as a
prevalent issue. TREAT did not decrease the average
consultation time. This was mostly due to comprehen-
sive coverage of topics and because clinicians had to be-
come familiar with the application. In general the
consultation time increased but at the same time more
topics were discussed, oftentimes in a more efficient and
collaborative way. The graphical user interface was
experienced as an improvement over the existing text-
based report letter provided by the routine outcome
monitoring (ROM) system. For most clinicians it became
easier to integrate the feedback of ROM-results into their
consultations with patients. This is an important finding,
as previous research has shown that CDAs that are diffi-
cult to integrate in existing care processes are not used by
clinicians after the experimental introduction [4].
In contrast with the positive responses on the visual
presentation of the individual ROM data, clinicians held
different opinions about the guideline-based treatment
recommendations. Some respondents indicated to be well
aware of existing guidelines and questioned the usefulness
of TREAT’s recommendations for daily clinical practice.
Other clinicians did use the recommendations to support
their clinical reasoning and to discuss the suggested inter-
ventions with their patients. Applicability was an issue for
some of the recommendations, as they were sometimes
experienced as too generic, required missing resources, or
had already been suggested or tried before by patients.
Only some clinicians mentioned interventions or treat-
ments that were started following treatment recommenda-
tions of TREAT. Cognitive behavioral therapy (CBT) and
eye movement desensitization and reprocessing (EMDR)
for example, were often recommended but in several
teams unavailable due to absence of a specialized psych-
ologist. This is in line with a regional psychosis care as-
sessment in The Netherlands, which revealed limited
availability for several guideline-based interventions [20].
Unavailability of resources has to be addressed in order to
successfully implement tools such as TREAT. The avail-
ability of recommended interventions is a prerequisite for
the efficacy of any CDA [1, 4].
Although clinicians were divided about the benefits of
the treatment recommendations, they all agreed that
TREAT contributed to more shared decision-making
(SDM). This is an important finding, as SDM in psych-
osis care is considered desirable, yet difficult to achieve
[21]. Making shared decisions can increase treatment ad-
herence and bolster empowerment of people with psych-
otic illness [22, 23]. SDM tries to change the traditional
power asymmetry between patients and clinicians [24].
Table 2 Summary of results
Views on TREAT’s: TREAT experienced as promoting TREAT experienced as limiting
1. Graphic representation Improved representation versus ROM-letter Successful feedback routines not in need of
change
2. Treatment recommendations Supported clinical reasoning and discussions with
patients
Too generic, comprehensive or inapplicable
3. Contextual factors Structured and complete screening routines Time pressure and unavailable resources
4. Effects on patients Sense of ownership and increased commitment Overwhelming and difficult
5. Effects on shared decision-
making
Facilitated shared decision-making Clinical decisions often remained unchanged
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The treatment recommendations and the graphic repre-
sentation of the ROM-results can contribute to SDM by
strengthening the exchange of information and the deci-
sional position of patients. Some clinicians noticed more
commitment from their patients during consultations
and a stronger sense of ownership of their ROM-data,
when using TREAT. It has to be noted that not all pa-
tients responded equally well to the application accord-
ing to clinicians, with some even having negative
responses. Concerns were also expressed about TREAT
in relation to personal recovery. Some clinicians stated
that the focus might still be too much on the symptoms,
burdens and problems, instead of strengths and the op-
portunities for support and treatment. However, increas-
ing SDM, autonomy and a sense of ownership over the
data during consultations, makes TREAT compatible
with personal recovery-oriented care [25].
We also utilized the Unified Theory of Acceptance
and Use of Technology (UTAUT) as presented in Fig. 1
to summarize our findings. Most interviewed clinicians
perceived TREAT as beneficial, user-friendly, easy to use
and experienced minimal burden. Therefore, the predict-
ive factors of performance and effort expectancy were
generally positively evaluated. There was little social in-
fluence because clinicians participated by their own
choice. They were often the only ones in their team to
join the study and experienced no external pressures to
work with TREAT. All respondents agreed that the fa-
cilitating conditions for implementation of the applica-
tion into the existing technical infrastructure and care
processes were met. Although no statistical generaliza-
tions can be made from these findings, all predictive fac-
tors of the UTAUT model were positively evaluated by
clinicians.
Strengths and limitations
Some limitations of this study need to be addressed.
One main limitation is a possible selection bias. We em-
phasized the importance of clinicians with skeptical atti-
tudes towards CDAs in general and TREAT in particular
while recruiting participants for this study. However, an
oversampling of clinicians with a more favorable attitude
cannot be ruled out. Furthermore, we only interviewed
clinicians that worked with the application on at least
three different occasions. We were interested in their
opinions because they had enough experience to evalu-
ate TREAT and help us understand the way in which
the application was used. Clinicians that worked with
TREAT only once or twice filled out a short anonymous
questionnaire to assess what complications they faced in
completing the intended four measurements. The most
common reasons were clinicians discontinuing their
work within the team or organization during the trial,
consulting insufficient patients that met the inclusion
criteria and logistical issues with planning and carrying
out measurements. Although not specifically mentioned
in the anonymous questionnaire, we cannot rule out the
possibility that some clinicians who were not included in
this study had stopped using TREAT after trying it once
or twice because of a perceived lack of benefit. The main
strength of this study is that we reached data saturation
with a diverse group of respondents. Both male and fe-
male psychiatrists and nurse practitioners from different
ages and with varying years of experience in psychosis
care were interviewed. No psychologist participated be-
cause they are underrepresented in psychosis care and
are less involved with the annual treatment plan evalua-
tions. Clinicians were recruited from teams in four dif-
ferent institutions from both urban and rural areas. The
diversity of respondents supports the generalizability of
our results.
Future research and improvements
This study provides insights into the use and evaluation
of TREAT by clinicians. Some questions about the ef-
fects of TREAT on daily clinical practice remain un-
answered. Furthermore, several improvements were
suggested for future use. Nearly all clinicians perceived
more SDM when working with TREAT. This requires
additional quantitative assessment. Furthermore, it is im-
portant to investigate the perspectives of patients be-
cause we do not known how they experience CDAs in
general and in psychosis care in particular. Our current
trial measures patients’ decisional conflict to assess
whether TREAT can facilitate SDM during consulta-
tions. Patients’ ratings of these consultations are also in-
cluded. According to clinicians, not all patients
responded equally well to TREAT, because the focus is
mainly on problems and less on the improvements in
treatment. For future development, clinicians often rec-
ommended incorporating ROM-data from previous
years to visualize positive health trends of patients in
treatment. They also suggested increasing the interactiv-
ity of TREAT. For example, by asking patients to
prioritize areas of interest or by adding small scripts with
relevant questions for identified problems. Furthermore,
multiple clinicians requested a similar application for
other mental illnesses such as depressive, borderline or
bipolar disorders. It is worthwhile to explore new ways
of collecting data, for example with the experienced
sampling method or by utilizing smart devices [26].
Moreover, newly developed models and guidelines for
the deployment of machine learning and artificial
intelligence in psychiatry, could improve new CDAs
[27]. A continuously growing body of evidence could
provide future designers with guidelines for development
and implementation of these tools.
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Conclusions
This article describes the use and evaluation by clinicians of
a computerized clinical decision aid in the treatment of
people with psychotic disorders. Most clinicians experienced
TREAT as easy to use and beneficial to their consultations.
The structured visual representation of ROM-results was
generally well-appreciated and provided cues to discuss treat-
ment planning with patients. The guideline based treatment
recommendations supported clinical reasoning but did not
seem to change most treatment decisions. The delivery and
applicability of the recommendations and the availability of
the recommended interventions need improvement for suc-
cessful implementation. Most patients seemed to appreciate
TREAT but not all, according to clinicians. The observation
that TREAT facilitates shared decision-making is promising
but requires further quantitative assessment. Future research
should also focus on patients’ perspectives to investigate
which patients respond best to CDAs in psychosis care. All
four predictors of the Unified Theory of Acceptance and Use
of Technology were positively evaluated by the majority of
clinicians. The full impact of TREAT on daily clinical prac-
tice still has to be assessed in the ongoing clinical trial and in
future research.
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